Skip to Content

The originating document has been archived. We cannot confirm the completeness, accuracy and currency of the content.

Ventipulmin Solution (Canada)

This page contains information on Ventipulmin Solution for veterinary use.
The information provided typically includes the following:
  • Ventipulmin Solution Indications
  • Warnings and cautions for Ventipulmin Solution
  • Direction and dosage information for Ventipulmin Solution

Ventipulmin Solution

This treatment applies to the following species:
Manufacturer: Boehringer

Clenbuterol hydrochloride Solution 30 µg (0.03 mg)/mL


Veterinary Use Only

DIN 00609102


The treatment of respiratory disease in horses constitutes a problem that has not been satisfactorily solved, even though many efficient measures are available today.

Pharmacological treatment finds its particular application at the level of either some exogenous stimulus, e.g., infection or some mechanism of bronchial obstruction, e.g. bronchospasm and/or accumulation of mucus. Bronchial obstruction due to the accumulation of secretions has been acted upon by mucolytic and expectorant drugs while bronchial obstruction caused by bronchospasm is relieved by sympathomimetic amines, anticholinergics, corticosteroids and xanthine derivatives.

The sympathomimetic amines have attracted special interest, their clinical application having originated in the demonstrated existence of cellular adrenergic receptors, which are called alpha, beta and gamma according to their response to stimuli. The beta receptors were further subdivided into beta-1 and beta-2. Stimulation of beta-2 receptors causes a relaxation of the smooth musculature of the bronchi and uterus, and of the beta-1 receptors of the intestinal tract and an increase in cardiac frequency. Especially interesting for the treatment of respiratory diseases are the beta-mimetic drugs used as bronchodilators. The phenomenon of bronchial spasm is determined by a defect in metabolism at the cellular level and is seen as an increased sensitivity in the bronchial musculature to some chemical mediators such as histamine, acetylcholine, etc., with the consequent phenomenon of bronchospasm. Beta-2 stimulant sympathomimetics, resolve bronchial spasm and consequently improve pulmonary ventilation. In many disease states, both subacute and chronic, the pathological state and the clinical phenomena can persist even when the etiological agent has ceased in its action, the disease still exists due to the continued disturbances of the physiological processes.


Clenbuterol, the active ingredient in Ventipulmin®, is a sympathomimetic amine and has been the subject of intensive research in both man and domestic animals. Due to its chemical structure, a high degree of selectivity for the beta-2 receptor sites in the body has been achieved providing intense bronchodilating properties with minimal effect on the cardiovascular system. Other properties attributed to Ventipulmin® include excellent absorption from the gastro-intestinal tract following oral administration so that the oral and parenteral dose rates are identical at 0.8 µg per kg of body weight.

The duration of effects is long-lasting and in the range of 6-8 hours after a single application. Twice daily administration by the oral route has been found to give a satisfactory level of medication, but where deemed necessary, treatment may be initiated by intravenous administration of the injectable solution.

Clinical Experience:

In clinical trials, the effects of Ventipulmin® on pulmonary function and clinical response were assessed in horses suffering from a variety of respiratory conditions including chronic obstructive pulmonary disease (COPD).

The horses responded by a marked decrease in intrathoracic pressure, a decrease in respiratory rate, an initial decrease followed by an increase in arterial oxygen partial pressure and clinical improvement. Duration of action of a single application was 6-8 hours. Other results showed a significant reduction in resistance to airflow and clinical improvement of the animals’ respiratory pattern.

There were no significant side effects due to the treatment in any of the clinical trials. In conditions where concurrent infection existed, supplementary treatment with chemotherapeutic and/or anti-infective agents was instituted.

Bronchodilator for the Treatment of Respiratory Disease in Horses:


A clear, colourless, aqueous solution. Each mL of solution contains 30 µg (0.03 mg) of 4-amino-α-(tert.-butylamino) methyl-3,5-dichlorobenzylalcohol hydrochloride (clenbuterol hydrochloride).

Preservative: 5 mg benzyl alcohol.

Uses: Treatment of respiratory disease in horses where it is considered that airway obstruction is due to bronchospasm. In cases accompanied by pyrexia, the parenteral administration of chemotherapeutic and/or anti-infective agents is recommended.

Dosage and Administration

Twice daily administration of 0.8 µg of clenbuterol per kg body weight. This is equivalent to 1.25 mL (containing 30 µg [0.03 mg] per mL) per 50 kg b.w. given by slow intravenous injection. Use aseptic technique. Treatment initiated with the injection solution can be continued with twice daily administration of Ventipulmin® syrup by the oral route.

Duration of action:

Approximately 8 hours after a single dose, 12 hours on repeated twice daily dosing.


Due to a potential risk of increasing the peripheral vasodilating effect of clenbuterol, it is not recommended that corticosteroids be used in conjunction with Ventipulmin®. Ventipulmin® antagonizes the effects of prostaglandin F2α and oxytocin. The action of Ventipulmin® is antagonized by β-adrenergic blocking agents.

Ventipulmin Solution Caution

If used during pregnancy, Ventipulmin® must be discontinued at the expected time of delivery, since uterine contractions may be abolished under its influence. The effect on fertility of breeding stallions has not been determined.

Side Effects

Infrequently, transient sweating, muscle tremors and mild tachycardia have been observed following intravenous administration. In each instance, the symptoms abated without complications or additional treatment.


Federal law prohibits the administration of this preparation to animals that produce food or that are intended for consumption as food.

Storage: Protect from light.

Boehringer Ingelheim (Canada) Ltd., Burlington, Ontario L7L 5H4

50 mL


NAC No.: 12300413

Customer Care No.:   800-567-1885
Technical Services No.:   1-877-565-5501
Every effort has been made to ensure the accuracy of the Ventipulmin Solution information published above. However, it remains the responsibility of the readers to familiarize themselves with the product information contained on the Canadian product label or package insert.

Copyright © 2018 North American Compendiums. Updated: 2018-04-26